As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

The latest trading day saw Pfizer (PFE) settling at $25.60, representing a -0.43% change from its previous close.

This article has been corrected to reflect that the senators asked UpScriptHealth to respond. In August 2024, Pfizer Inc ...

Morgan Stanley lowered the firm’s price target on Arvinas (ARVN) to $12 from $48 and keeps an Equal Weight rating on the shares after the ...

Guggenheim analyst Vamil Divan maintained a Buy rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Even though Pfizer Inc.'s ( NYSE:PFE ) recent earnings release was robust, the market didn't seem to notice. We ...

Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...

LM Real Estate Partners of New York sold Lightstone the property — the firm paid $9 million for it in 2019. The combined ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March ...

Shares of Pfizer Inc. PFE slid 2.44% to $25.99 Tuesday, on what proved to be an all-around poor trading session for the stock ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...